Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase
- 1 December 2002
- journal article
- review article
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 3 (4) , 57-68
- https://doi.org/10.1016/s1567-5688(02)00045-4
Abstract
No abstract availableKeywords
This publication has 109 references indexed in Scilit:
- Cellular Source(s) of Platelet-Activating-Factor Acetylhydrolase Activity in PlasmaBiochemical and Biophysical Research Communications, 1999
- Apolipoprotein B-100 Conformation and Particle Surface Charge in Human LDL Subspecies: Implication for LDL Receptor InteractionBiochemistry, 1998
- Lipoprotein lipase in relation to inflammatory activity in rheumatoid arthritisJournal of Internal Medicine, 1996
- Pefabloc, 4-[2-aminoethyl]benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible inhibitor of PAF-degrading acetylhydrolaseBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1996
- PAF-Degrading Acetylhydrolase Is Preferentially Associated With Dense LDL and VHDL-1 in Human PlasmaArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Human Atherosclerotic Plaque Contains Both Oxidized Lipids and Relatively Large Amounts of α-Tocopherol and AscorbateArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Platelet-activating factor formation during oxidative modification of low-density lipoprotein when PAF-acetylhydrolase has been inactivatedBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1994
- Distribution of PAF-acetylhydrolase activity in human plasma low-density lipoprotein subfractionsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1994
- Plasma degradation of platelet-activating factor in severely ill patients with clinical sepsisCritical Care Medicine, 1994
- HMG-CoA Reductase Inhibitors for Treatment of HypercholesterolemiaNew England Journal of Medicine, 1988